Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

This study observed that DDAIP-HCl enhanced the permeation of minoxidil through human cadaver skin, suggesting potential for improved treatment efficacy in male pattern hair loss.

Female-marketed minoxidil foam is more expensive than male-marketed, but generic and bulk options can reduce this gap.

This study found that morroniside enhanced hair follicle growth and transition through the Wnt/β-catenin signaling pathway in a mouse model, suggesting its potential as a treatment for hair loss.

This study found that a proniosomal gel formulation of finasteride increased anagen hair count in male volunteers with androgenic alopecia by 42.85% compared to the control group.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

In this study, PMC was identified as a promising plant for nourishing hair, with effective hair growth promotion and 5α-reductase inhibition observed in both laboratory and animal studies for androgenetic alopecia treatment.

This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.

This study found that topical minoxidil significantly increased terminal hair growth in men with early male pattern baldness compared to placebo over a 4-month period.

This review found limited evidence on the effectiveness of different antiandrogens for feminization in transgender women, suggesting cyproterone acetate, leuprolide, and medroxyprogesterone acetate may better suppress testosterone than spironolactone or estradiol alone.

Sublingual minoxidil significantly improves hair growth in transgender individuals on testosterone therapy.

This study found that finasteride blocked the progesterone-induced increase in spike-wave discharges in rats, suggesting that this effect of progesterone is mediated by its metabolite allopregnanolone.

In this randomized, controlled trial, the researchers observed that sub-lingual minoxidil at doses of 1.35 mg and 4.05 mg, but not 0.45 mg, significantly increased hair fibre diameter in men with male androgenetic alopecia over 24 weeks, suggesting a dose-dependent reversal of follicle miniaturization.

This study evaluated high-dose oral minoxidil treatment in 57 patients with androgenetic alopecia and found it improved hair density by 10-30% in most cases, but 24.6% experienced adverse effects like hypertrichosis and tachycardia, indicating further research is needed to optimize safety and efficacy.

This study established consensus-based guidelines for using low-dose oral and topical minoxidil in managing pattern hair loss for patients undergoing hair transplant surgery, recommending specific dosages, monitoring procedures, and timing for initiation post-surgery.

This study found that certain compounds from Chaga mushrooms stimulated the proliferation of human hair follicle cells more effectively than minoxidil, suggesting potential for hair-growth treatments.

In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.

This study found that nanostructured lipid carriers enhanced the skin penetration and retention of minoxidil compared to solid lipid nanoparticles, suggesting they could be a promising method for topical delivery.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

5% minoxidil foam helps women with thinning hair.

This study found that after 12 weeks of taking 10 mg of S-equol daily, over 90% of participating perimenopausal and menopausal women reported improvements in symptoms like hot flashes, night sweats, and sleep disturbances.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.